Durable Responses Reported With Pembrolizumab in Heavily Pretreated Extensive-Stage Small Cell Lung Cancer


Get Permission

The programmed cell death protein 1 (PD-1) inhibitor pembrolizumab (Keytruda) has shown durable antitumor activity in patients with extensive-stage small cell lung cancer (SCLC) that expresses programmed cell death ligand 1 (PD-L1), according to an update of the KEYNOTE-028 trial.1

Patrick A. Ott, MD, PhD

Patrick A. Ott, MD, PhD

“Median overall survival for extensive-stage small cell lung cancer is 8 to 12 months, and no therapy has improved on the 15% to 20% response rate and 30% 1-year overall survival provided by second-line topotecan,” commented lead investigator Patrick A. Ott, MD, PhD, a medical oncologist and Clinical Director of the Center for Immuno-Oncology at the Dana-Farber Cancer Institute in Boston.

However, the trial’s updated data showed that after a median follow-up of 9.8 months, 33.3% of patients had a complete or partial response to pembrolizumab, with responses lasting for a median of 19.4 months. Additionally, the 1-year rate of overall survival with the immune checkpoint inhibitor approached 40%, and the favorable safety profile seen initially was unchanged

“Pembrolizumab demonstrated meaningful antitumor activity in previously treated patients with PD-L1–positive small cell lung cancer. Responses were durable,” Dr. Ott concluded. “The safety profile was consistent with the prior experience [in other tumor types], and it was identical with longer follow-up.”

Ongoing trials of pembrolizumab for extensive-stage SCLC—one looking at maintenance after combination chemotherapy (NCT02359019) and another looking at its combination with chemotherapy in the first-line setting (NCT02580994, REACTION trial)—should help further clarify its role in this disease, he maintained.

Study Details

KEYNOTE-028 is a phase Ib multicohort study among patients with PD-L1–positive advanced solid tumors who experienced treatment failure of or were unable to receive standard therapy.

Immunohistochemical staining for PD-L1 was done in a central laboratory, according to Dr. Ott. Positivity required membranous expression by at least 1% of tumor cells and associated inflammatory cells or positive staining in the stroma. Overall, just 28.6% of the patients with SCLC screened for the trial were found to have PD-L1–positive tumors.

Patients were treated with pembrolizumab at 10 mg/kg every 2 weeks. They underwent assessment of response every 8 weeks for the first 6 months and every 12 weeks thereafter.

Among the 24 patients ultimately enrolled, all had received chemotherapy, and 87.5% had received 2 or more previous lines of therapy during the entire course of their disease. Some 20.8% had stable brain metastases

Toxicity and Survival

“The toxicity was overall very consistent with prior experience with pembrolizumab,” Dr. Ott revealed. “Most toxicity was grade 1 and 2, with the most common side effects being arthralgias, asthenia, rash, diarrhea, and fatigue.”

Adverse events of any grade occurred in 66.7% of patients, and adverse events of grade 3 or worse occurred in 8.3%. Some 12.5% experienced immune-related adverse events—thyroiditis, infusion-site reaction, cytokine-release syndrome, or colitis—with no cases of pneumonitis.

According to investigator review, the median duration of progression-free survival was 1.9 months, and the 1-year rate was 23.8%. The median duration of overall survival was 9.7 months, and the 1-year rate was 37.7%.

“There is quite an encouraging plateau of the survival curve going out to 24 months,” Dr. Ott noted. ■

Disclosure: The trial was supported by Merck. Dr. Ott has received research funding from Bristol-Myers Squibb, Merck, ArmoBiosciences, AstraZeneca/MedImmune, and Celldex and honoraria from Merck, Genentech, Alexion, CytomX, and Celldex.

Reference

1. Ott PA, Felip E, Hiret S, et al: Pembrolizumab in patients with extensive-stage small cell lung cancer: Updated survival results from KEYNOTE-028. 2016 World Conference on Lung Cancer. Abstract OA05.01. Presented December 5, 2016.


Related Articles

Expert Point of View: Leora Horn, MD, MSc


The caveat is that this was a highly selected cohort of patients.
— Leora Horn, MD, MSc

Tweet this quote

The KEYNOTE-028 results confirm that pembrolizumab ­(Keytruda) is active in extensive-stage small cell lung cancer (SCLC) and lay to rest safety concerns...

Advertisement

Advertisement

Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.